Mizuho Securities Upgrades DepoMed Inc (DEPO) to Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Wall St rises on AI gains as oil slides, Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips below $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
- AMD stock jumps as chip rally builds ahead of summit
DepoMed (DEPO) PT Lowered to $21 at Piper Jaffray
May 6, 2016 9:09 AM EDTPiper Jaffray analyst David Amsellem lowered his price target on DepoMed Inc (NASDAQ: DEPO) to $21.00 (from $23.00) and reiterated a Overweight rating following Q1 results.
Amsellem commented, "Depomed reported adjusted diluted EPS of $0.12 on revenues of $105M, versus Street estimates of $0.17 and $107M, respectively... More
Depomed (DEPO) Misses Q1 EPS by 5c
May 5, 2016 4:00 PM EDTDepomed (NASDAQ: DEPO) reported Q1 EPS of $0.12, $0.05 worse than the analyst estimate of $0.17. Revenue for the quarter came in at $104.8 million versus the consensus estimate of $107.1 million.
For earnings history and earnings-related data on Depomed (DEPO) click here.
... More